In conclusion, with the prospects for long-time survival greatly improved by immunotherapy, our results provide timely and valuable information on the prognostic roles of CD4+ T cells in advanced NSCLC patients treated with chemoIO. The gene discussed is CD4; the disease is non-small cell lung carcinoma.